Brokerages forecast that Aduro BioTech Inc (NASDAQ:ADRO) will report earnings of ($0.36) per share for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Aduro BioTech’s earnings, with estimates ranging from ($0.46) to ($0.30). Aduro BioTech reported earnings of ($0.44) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 18.2%. The company is expected to report its next earnings results on Wednesday, March 7th.
On average, analysts expect that Aduro BioTech will report full year earnings of ($1.28) per share for the current year, with EPS estimates ranging from ($1.39) to ($1.22). For the next year, analysts expect that the firm will report earnings of ($1.28) per share, with EPS estimates ranging from ($1.66) to ($0.78). Zacks’ EPS calculations are an average based on a survey of analysts that cover Aduro BioTech.
A number of analysts recently weighed in on the company. HC Wainwright set a $18.00 price target on Aduro BioTech and gave the company a “buy” rating in a research note on Tuesday, October 17th. Oppenheimer initiated coverage on Aduro BioTech in a report on Monday, October 30th. They set a “buy” rating and a $15.00 price objective on the stock. BidaskClub downgraded Aduro BioTech from a “hold” rating to a “sell” rating in a report on Saturday, December 9th. Finally, Canaccord Genuity set a $30.00 target price on Aduro BioTech and gave the stock a “buy” rating in a report on Thursday, December 14th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $17.71.
In related news, VP Jennifer Lew sold 6,600 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $9.46, for a total value of $62,436.00. Following the completion of the transaction, the vice president now owns 68,938 shares in the company, valued at approximately $652,153.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Stephen T. Isaacs sold 16,400 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $7.96, for a total transaction of $130,544.00. Following the completion of the transaction, the chief executive officer now owns 190,321 shares of the company’s stock, valued at approximately $1,514,955.16. The disclosure for this sale can be found here. Insiders sold a total of 223,391 shares of company stock valued at $1,897,707 in the last 90 days. 6.60% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of ADRO. Legal & General Group Plc lifted its stake in Aduro BioTech by 11.2% in the second quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock worth $118,000 after acquiring an additional 1,043 shares during the period. Fox Run Management L.L.C. acquired a new position in Aduro BioTech in the third quarter valued at $127,000. SG Americas Securities LLC acquired a new position in Aduro BioTech in the third quarter valued at $167,000. Trexquant Investment LP acquired a new position in Aduro BioTech in the third quarter valued at $175,000. Finally, Nisa Investment Advisors LLC increased its stake in Aduro BioTech by 2,294.1% in the fourth quarter. Nisa Investment Advisors LLC now owns 24,420 shares of the biotechnology company’s stock valued at $183,000 after purchasing an additional 23,400 shares during the last quarter. Hedge funds and other institutional investors own 45.14% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was first reported by Week Herald and is the property of of Week Herald. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://weekherald.com/2018/02/15/zacks-analysts-anticipate-aduro-biotech-inc-adro-will-post-earnings-of-0-36-per-share.html.
Aduro BioTech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.